U.S. Markets closed

Curis, Inc. (CRIS)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
11.49-0.72 (-5.90%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close11.87
Open11.98
Bid11.48 x 1300
Ask12.21 x 3000
Day's Range11.68 - 12.35
52 Week Range0.62 - 13.44
Volume3,014,956
Avg. Volume2,139,353
Market Cap1.052B
Beta (5Y Monthly)3.07
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
    PR Newswire

    Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that on April 1, 2021, the independent Compensation Committee of the Board of Directors of Curis approved the grant of inducement stock options to purchase a total of 167,300 shares of Curis common stock to five new employees, with a grant date of April 1, 2021 (the "Q2 2021 Inducement Grants").

  • Curis to Present at 20th Annual Needham Virtual Healthcare Conference
    PR Newswire

    Curis to Present at 20th Annual Needham Virtual Healthcare Conference

    Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that James Dentzer, President and Chief Executive Officer of Curis, will present a company overview at the 20th Annual Needham Virtual Healthcare Conference on Tuesday, April 13, 2021 at 10:15 am ET.

  • Curis Reports Fourth Quarter and Year-End 2020 Financial Results
    PR Newswire

    Curis Reports Fourth Quarter and Year-End 2020 Financial Results

    Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today reported its financial results for the fourth quarter and year ended December 31, 2020.